Takeda Files NDA for Cabometyx (cabozantinib) to MHLW for Advanced Renal Cell Carcinoma in Japan

 Takeda Files NDA for Cabometyx (cabozantinib) to MHLW for Advanced Renal Cell Carcinoma in Japan

Takeda Files NDA for Cabometyx (cabozantinib) to MHLW for Advanced Renal Cell Carcinoma in Japan

Shots:

  • The submission is based on METEOR, CABOSUN and Takeda’s bridging study. METEOR & CABOSUN studies result assessing Cabometyx vs everolimus & sunitinib in patients with RCC + prior treated with at least one VEGFR-TKI inhibitor & untreated advanced RCC with intermediate/poor-risk disease respectively
  • In Q2’19, Exelixis is expected to receive $10M as milestones from Takeda under a license agreement signed by the companies in H1’17. Additionally, Takeda has an option to co-fund ongoing P-III CheckMate 9ER study assessing cabozantinib + nivolumab vs sunitinib for untreated advanced RCC
  • Cabometyx (cabozantinib) is a VEGFR-TKI inhibitor and is approved for the treatment of patients with advanced RCC & HCC previously treated with sorafenib. In 2016, Ipsen acquired exclusive rights to develop & commercialize Cabometyx (Ex the US & Japan) from Exelixis

Click here to read full press release/ article | Ref: Exelixis | Image: Behance

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post